You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 11, 2025

Drug Price Trends for METHYLDOPA


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for METHYLDOPA

Best Wholesale Price for METHYLDOPA

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type
METHYLDOPA 250MG TAB Chartwell RX LLC 62135-0321-18 180 1282.49 7.12494 EACH 2023-12-28 - 2025-08-31 FSS
METHYLDOPA 250MG TAB Chartwell RX LLC 62135-0321-90 90 641.24 7.12489 EACH 2023-12-28 - 2025-08-31 FSS
METHYLDOPA 500MG TAB Chartwell RX LLC 62135-0322-18 180 1709.99 9.49994 EACH 2023-12-28 - 2025-08-31 FSS
METHYLDOPA 500MG TAB Chartwell RX LLC 62135-0322-90 90 854.99 9.49989 EACH 2023-12-28 - 2025-08-31 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Unit >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Methyldopa Market Analysis and Price Projections

Introduction to Methyldopa

Methyldopa, also known as alpha (α) methyldopa, is a centrally acting antiadrenergic agent used primarily to treat hypertension (high blood pressure). It works by lowering specific chemicals in the blood, promoting blood vessel relaxation, and reducing blood pressure. Here’s a comprehensive analysis of the methyldopa market, including its current state, growth projections, and key drivers.

Market Size and Growth

The methyldopa market has experienced significant growth in recent years. As of 2023, the global market size was valued at $9.31 billion and is expected to grow to $10.24 billion in 2024, with a compound annual growth rate (CAGR) of 10%[1][2][3].

Looking ahead, the market is projected to continue its rapid growth, reaching $15.14 billion by 2028 at a CAGR of 10.3%. This growth is driven by several key factors, including improvements in diagnostic techniques, the expansion of public health campaigns, increased research funding, development of healthcare infrastructure, and a rise in hypertension cases[1][2][3].

Key Drivers of the Market

Increasing Awareness and Management of Hypertension

The growing awareness about hypertension and the focus on managing chronic diseases are significant drivers of the methyldopa market. Hypertension, which affects a substantial portion of the global population, is driven by factors such as poor diet, lack of physical activity, obesity, and elevated stress levels. For instance, the Heart Foundation reported that about 23% of adults in Australia have hypertension, with a higher prevalence among men[1].

Development of Generic Versions

The development and increasing preference for generic versions of methyldopa are crucial for market growth. Generic medications are cost-effective alternatives to brand-name drugs, offering equivalent quality, performance, and safety. In the U.S., generics constitute approximately 90% of the prescription drug market volume, reflecting a widespread adoption also seen in other countries like the U.K., Australia, China, and Germany[2][3].

Aging Population and Rising Obesity Rates

An aging population and rising obesity rates are also contributing to the growth of the methyldopa market. These demographic changes lead to higher incidence rates of chronic diseases, including hypertension, which in turn increases the demand for antihypertensive medications like methyldopa[1][2][3].

Increasing Healthcare Expenditure

Rising healthcare expenditure is another key factor propelling the growth of the methyldopa market. Increased spending on healthcare goods and services, driven by factors such as population aging, rising chronic disease prevalence, and greater demand for healthcare services and medications, boosts the demand for methyldopa. For example, in the UK, healthcare spending reached $363.44 billion in 2021, with an average expenditure of $5,422 per person[2][3].

Market Segmentation

The methyldopa market is segmented by type, purity, and application.

By Type

  • Oral: Methyldopa taken by mouth is the most common form and is widely used for treating hypertension.
  • Intravenous Drip: Used in more severe cases or when oral administration is not feasible[2][3].

By Purity

  • Purity: =98%
  • Purity: =99%: Different purity levels cater to various medical needs and regulatory standards[2][3].

By Application

  • Parkinsonism: Methyldopa is sometimes used to treat symptoms of Parkinson's disease.
  • Hepatic Coma: It can also be applied in the treatment of hepatic coma, although this is less common[2][3].

Regional and Country Analysis

The methyldopa market is split by region and country, with significant growth expected in various regions due to differing healthcare infrastructures and population demographics.

  • Asia-Pacific: This region is expected to see substantial growth due to expanding healthcare infrastructure, increasing awareness about hypertension, and government initiatives to enhance accessibility to affordable medications[2].
  • North America and Europe: These regions also show promising growth due to high healthcare expenditure, advanced diagnostic techniques, and a strong focus on managing chronic diseases[1][2][3].

Trends and Innovations

Several trends are expected to shape the future of the methyldopa market:

  • Advancements in Drug Delivery Systems: Innovations in drug delivery systems will improve the efficacy and convenience of methyldopa administration.
  • Biopharmaceutical Innovations: New biopharmaceutical technologies will enhance the production and quality of methyldopa.
  • Digital Health Solutions: The integration of digital health solutions will improve patient monitoring and treatment adherence.
  • Artificial Intelligence in Healthcare: AI will play a crucial role in diagnosing hypertension and personalizing treatment plans[1][2][3].

Methyldopa API Market

The Methyldopa Active Pharmaceutical Ingredient (API) market is also growing, driven by the increasing prevalence of hypertension and related cardiovascular diseases. This market was valued at $0.52 billion in 2022 and is projected to reach $0.85 billion by 2030, growing at a CAGR of 6.2% from 2024 to 2030. The demand for Methyldopa API is further stimulated by growing awareness regarding maternal health and the increasing usage of generics[4].

Price Projections

The cost of methyldopa can vary based on the form and purity of the medication. Here are some price points for methyldopa:

  • 500 mg Oral Tablet: The cost for a supply of 90 tablets can range from $29 to $49, depending on the quantity and pharmacy[5].

Given the growing demand and advancements in healthcare, the prices of methyldopa are likely to remain competitive, especially with the rise of generic versions.

Key Takeaways

  • The methyldopa market is expected to grow significantly, reaching $15.14 billion by 2028.
  • Key drivers include increasing awareness about hypertension, development of generic versions, an aging population, and rising healthcare expenditure.
  • The market is segmented by type (oral and intravenous), purity, and application.
  • Trends such as advancements in drug delivery systems, biopharmaceutical innovations, and the integration of digital health solutions will shape the market.
  • The Methyldopa API market is also growing, driven by the increasing prevalence of hypertension and related cardiovascular diseases.

FAQs

What is methyldopa used for?

Methyldopa is primarily used to treat hypertension (high blood pressure) by acting as a central alpha-2 adrenergic agonist. It can also be used to treat symptoms of Parkinson's disease and hepatic coma.

How does methyldopa work?

Methyldopa works by lowering specific chemicals in the blood, promoting blood vessel relaxation, and reducing blood pressure.

What are the main types of methyldopa?

The main types of methyldopa are oral and intravenous drip, available in various purity levels such as =98% and =99%.

What are the key drivers of the methyldopa market?

Key drivers include increasing awareness about hypertension, development of generic versions, an aging population, rising obesity rates, and increasing healthcare expenditure.

How is the methyldopa market segmented?

The market is segmented by type (oral and intravenous), purity (e.g., =98%, =99%), and application (e.g., Parkinsonism, hepatic coma).

What trends are expected to shape the future of the methyldopa market?

Trends include advancements in drug delivery systems, biopharmaceutical innovations, developments in clinical trial methodologies, the integration of digital health solutions, and the application of artificial intelligence in healthcare.

Sources

  1. Research and Markets: Alpha (α) Methyldopa Market Report 2024.
  2. The Business Research Company: Alpha Methyldopa Market Report 2024.
  3. GII Research: Alpha (α) Methyldopa Global Market Report 2024.
  4. GitHub: Methyldopa API Market Key Drivers and Forecast 2025-2032.
  5. Drugs.com: Methyldopa Prices, Coupons, Copay Cards & Patient Assistance.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.